JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2015, Vol. 53 ›› Issue (9): 71-79.doi: 10.6040/j.issn.1671-7554.0.2015.514

Previous Articles     Next Articles

Serum TK1 for the diagnosis of cancer in Chinese patients: a Meta-analysis

LIU Jingsheng1, LIU Guihua1, DU Kun1, ZHAO Qian2, WENG Shaobo1, ZHAO Xueying1, ZHANG Xizhuang1, JIN Xunbo3   

  1. 1. Department of Urology, North China Petroleum Administration Bureau General Hospital, Renqiu 062552, Hebei, China;
    2. Department of Pharmacy, North China Petroleum Administration Bureau General Hospital, Renqiu 062552, Hebei, China;
    3. Department of Minimally Invasive Urology Center, Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong, China
  • Received:2015-05-25 Online:2015-09-10 Published:2015-09-10
  • Contact: 金讯波。E-mail:16365451@qq.com E-mail:16365451@qq.com

PDF (PC)

760

Abstract: Objective To evaluate significance of thymidine kinase 1 (TK1) detection in the diagnosis of malignant tumors in Chinese patients. Methods Clinical trials on TK1 detection published during Jan. 2008 to Mar 2015 were searched in databases of CNKI and Wan Fang. Revman 5.2 and Meta Disc 1.4 were used to perform the Meta-analysis.Results A total of 415 relevant articles were retrieved and 45 trials with 2,976 cancer patients (all diagnosed by the gold standard) were involved. Meta-analyses showed that the heterogeneity among studies was high, and the pooled Results suggested a moderate diagnostic efficacy. The sensitivities for lung cancer, breast cancer, gynecological cancer, prostatic cancer, gastric cancer, intestinal cancer and esophagus cancer were 0.508, 0.638, 0.524, 0.656, 0.583, 0.546, and 0.681, respectively. The specificities were 0.973, 0.932, 0.940, 0.925, 0.941, 0.947, and 0.967. Conclusion TK1 detection may have certain value in the early diagnosis and screening of malignant cancers, but it can not be serveed as an independent reference test. More high quality trials are required to confirm the significance of TK1 detection.

Key words: Thymidine kinase 1, Cancer, Specificity, Meta-analysis, Sensitivity

CLC Number: 

  • R730.4
[1] Aufderklamm S, Todenhöfer T, Gakis G, et al. Thymidine kinase and cancer monitoring[J]. Cancer Letters, 2012, 316(1):6-10.
[2] Chen YL, Eriksson S, Chang ZF. Regulation and functional contribution of thymidine kinase 1 in repair of DNA damage[J]. J Biol Chem, 2010, 285(35):27327-27335.
[3] Xu Y, Shi QL, Ma H, et al. High thymidine kinase 1 (TK1) expression is a predictor of poor survival in patients with pT1 of lung adenocarcinoma[J]. Tumour Biol, 2012, 33(2):475-483.
[4] Stalhandske P, Wang L, Westberg S, et al. Homogeneous assay for realtime and simultaneous detection of thymidine kinase 1 and deoxycytidine kinase activities[J]. Anal Biochem, 2013, 432(2):155-164.
[5] Xiang Y, Zeng H, Liu X, et al. Thymidine kinase 1 as a diagnostic tumor marker is of moderate value in cancer patients: A meta-analysis[J]. Biomed Rep, 2013, 1(4):629-637.
[6] 刘鹏飞, 姬舒荣.血清胸苷激酶1在恶性肿瘤筛查和复发转移监测中研究进展[J].中华临床医师杂志:电子版, 2013, 7(23):10858-10860. LIU Pengfei, JI Shurong. Progress advances on serum thymidine kinase 1 in screening and monitoring of malignant tumor recurrence and metastasis[J/CD]. Chin J Clinicians (Electronic Edition), 2013, 7(23):10858-10860.
[7] Chen YL, Eriksson S, Chang ZF. Regulation and functional contribution of thymidine kinase 1 in repair of DNA damage[J]. J Biol Chem, 2010, 285(35):27327-27335.
[8] Zhou J, He E, Skog S. The proliferation marker thymidine kinase 1 in clinical use[J]. Mol Clin Oncol, 2013, 1(1):18-28.
[9] Nisman B, Allweis T, Kaduri L, et al. Serum thymidine kinase 1 activity in breast cancer[J]. Cancer Biomark, 2010, 7(2):65-72.
[10] He E, Xu XH, Guan H, et al. Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin's lymphoma[J]. Nucleosides Nucleotides Nucleic Acids, 2010, 29(4-6):352-358.
[11] Wu BJ, Li WP, Qian C, et al. Increased serum level of thymidine kinase 1 correlates with metastatic site in patients with malignant melanoma[J]. Tumour Biol, 2013, 34(2):643-648.
[12] 邹雄. 胸苷激酶1是恶性肿瘤预后判断的动态标志[J]. 实用检验医师杂志, 2013, 5(2):67-71. ZOU Xiong. Serum thymidine kinase 1 activity is a dynamic marker of the prognosis of malignant tumor[J]. Chinese Journal of Laboratory Pathologist, 2013, 5(2):67-71.
[13] 郭丽香, 刘树业. 胸苷激酶1—新型的细胞增殖动力学标志[J].哈尔滨医药, 2014(5):316-317. GUO Liuxiang, LIU Shuye. Thymidine kinase 1-a new cell proliferation marker[J]. Harbin Medical Journal, 2014(5):316-317.
[14] 徐文静, 刘德干. 血清胸苷激酶1与肿瘤[J]. 国际肿瘤学杂志, 2013, 40(9):643-645. XU Wenjing, LIU Degan. Serum thymidine kinase 1 and cancer[J]. Journal of International Oncology, 2013, 40(9):643-645.
[15] Chen G, He C, Li L, et al. Nuclear TK1 expression is an independent prognostic factor for survival in pre-malignant and malignant lesions of the cervix[J]. BMC Cancer, 2013, 13:249. doi: 10.1186/1471-2407-13-249.
[16] Chen Y, YingM, Chen Y, et al. Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings[J]. Int J Clin Oncol, 2010, 15(4):359-368.
[17] Xu Y, Liu B, Shi QL, et al. Thymidine kinase 1 is a better prognostic marker than Ki-67 for pT1 adenocarcinoma of the lung[J]. Int J Clin Exp Med, 2014, 7(8):2120-2128.
[18] Chen ZH, Huang SQ, Wang Y, et al. Serological thymidine kinase 1 is a biomarker for early detection of tumors-A health screening study on 35,365 people, using a sensitive chemiluminescent dot blot assay[J]. Sensors, 2011, 11(12):11064-11080.
[19] Bolayirli M, Papila C, Korkmaz GG, et al. Serum thymidine kinase 1 activity in solid tumor (breast and colorectal cancer) patients treated with adjuvant chemotherapy[J]. J Clin Lab Anal, 2013, 27(3):220-226.
[20] Chen F, Tang L, Xia T, et al. Serum thymidine kinase 1 levels predict cancer-free survival following neoadjuvant, surgical and adjuvant treatment of patients with locally advanced breast cancer[J]. Mol Clin Oncol, 2013, 1(5):894-902.
[21] Huang ZH, Tian XS, Li R, et al. Elevated thymidine kinase 1 in serum following neoadjuvant chemotherapy predicts poor outcome for patients with locally advanced breast cancer[J]. Exp Ther Med, 2012, 3(2):331-335.
[1] LIN Mingxia, LIU Guibin, MA Yanhua, LIAN Zhaoyu, REN Yangyang. ATPase copper transporting alpha mediated cuproptosis pathway and its value in cancer therapy [J]. Journal of Shandong University (Health Sciences), 2026, 64(4): 117-124.
[2] HUANG Peiwen, WANG Xudong. A new drug for non-small cell lung cancer: Telisotuzumab Vedotin, an antibody-drug conjugate targeting c-Met protein [J]. Journal of Shandong University (Health Sciences), 2026, 64(3): 124-130.
[3] GU Chunqing, GUO Ruisi, ZHOU Qinqin, LIU Henghui, BA Wanyu, SUN Shiling, WANG Bing, ZHENG Yuling, WU Suhui. Mechanism of Suanzaoren-Yuanzhi drug pair in the treatment of breast cancer related insomnia based on network pharmacology and animal experiments [J]. Journal of Shandong University (Health Sciences), 2026, 64(1): 99-108.
[4] LI Jing, JU Weihang, LIU Ke. Pan-cancer cell type-specific gene-gene co-expression pattern [J]. Journal of Shandong University (Health Sciences), 2025, 63(9): 31-39.
[5] LI Xuekai, SUN Linhan, LIU Duanrui, NI Yang. Research progress on the function and mechanism of lactylation in the process of tumor inflammation and cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(9): 65-76.
[6] LI Ziqi, WEI Yanruoxue, LIU Xiaohan, LIU Chuncheng, ZHAO Ran, LIU Yukun. The functional role and clinical significance of lncRNA HEATR3-AS1 in colorectal cancer tumorigenesis and progression [J]. Journal of Shandong University (Health Sciences), 2025, 63(9): 108-115.
[7] ZHANG Runze, XUE Fuzhong, YANG Fan. Cancer subtype clustering via multimodal decoupled contrastive learning [J]. Journal of Shandong University (Health Sciences), 2025, 63(8): 51-60.
[8] LI Qian, YANG Fan, XUE Fuzhong. Multi-cancer risk prediction model based on multi-modal data fusion [J]. Journal of Shandong University (Health Sciences), 2025, 63(8): 79-85.
[9] LIU Baoguo, SONG Xiang, ZHAO Xiaowen, MAO Yali. Application value of serum STAT5B and NKAIN1 mRNA detection in breast cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(7): 68-74.
[10] WANG Lei, CHANG Xiao, WANG Zimeng, LI Jiaojiao, CUI Shujun, YANG Fei, ZHU Yuexiang. Predictive value of intratumoral and peritumoral DCE-MRI imaging histology for progression-free survival in patients with cervical cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(6): 45-54.
[11] WANG Xuemei, YANG Hao, SONG Yang, CHENG Shichao, ZHANG Tingting, WANG Yanchun. Causal association of antidiabetic drugs with female malignant tumours: a two-sample Mendelian randomisation study [J]. Journal of Shandong University (Health Sciences), 2025, 63(6): 67-77.
[12] ZHU Yongcai, XIE Yan, QI Qiuchen, LI Peilong, WANG Chuanxin, DU Lutao. Value of a combined model based on ATM gene methylation of peripheral blood mononuclear cells in the early diagnosis of pancreatic cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(6): 78-88.
[13] WEN Xuelong, LIU Anhui, CHEN Jingwei, WU Mengting, YANG Min. A Meta-analysis of the timing of coronary artery bypass grafting surgery for acute non-ST myocardial infarction [J]. Journal of Shandong University (Health Sciences), 2025, 63(5): 60-70.
[14] ZHAO Hanqing, ZHOU Xinrui, LI Zijian, TANG Xing. Application of circulating tumor cells combined with serological detection in non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(5): 79-85.
[15] DU Xue, LI Chunxia, LIU Yunxia, ZHANG Tao. Dynamic prediction model for the colorectal cancer patients prognosis based on MFPC-Cox [J]. Journal of Shandong University (Health Sciences), 2025, 63(5): 101-110.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd